1. Venofer® [package insert]. Shirley, NY: American Regent, Inc. 6/2011.
  2. Ferrlecit® [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC, Vial 10/2010.
  3. Nulecit® [package insert]. Corona, CA: Watson Pharma Inc. 1/2010
  4. American Medical Association. United States Adopted Name Council Adopted Names page. Available at: http://www.ama-assn.org/ ama/pub/about-ama/our-people/coalitions-consortiums/united-states-adopted-names-council/adopted-names.shtml. Accessed June 19, 2009.
  5. American Society of Health System Pharmacists. ASHP Guidelines on Quality Assurance for Pharmacy-Prepared Sterile Products. Am J Health-Syst Pharm. 2000; 57:1150-69.
  6. Groman EV, Paul KG, Frigo TB, Bengele H, Lewis JM, inventors; Advanced Magnetics Inc., assignee. Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohydrate derivatives. US Patent 6 599 498. July 29, 2003.
  7. INFeD® [package insert] Morristown, NJ: Watson Pharma, Inc Rev. 9/2009.
  8. Dexferrum® [package insert]. Shirley, NY: American Regent, Inc. Rev. 8/2008.
  9. Feraheme™ [package insert]. Lexington, MA: AMAG Pharmaceuticals, Inc. 6/2011.
  10. Lawrence R. Development and Comparison of Iron Dextran Products. PDA. J Pharm Sci Technol. 1998;52(5):190-197.




 
American Regent. Enriching the lives of anemia patients. ™

IMPORTANT SAFETY INFORMATION:

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer® (iron sucrose injection, USP). Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer® immediately. Monitor patients for signs and symptoms of hypersensitivity during and after Venofer® administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer® when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

Venofer® may cause clinically significant hypotension. Monitor for signs and symptoms of hypotension following each administration of Venofer®. Hypotension following administration of Venofer® may be related to rate of administration and total dose delivered.

Venofer® is contraindicated in patients with known hypersensitivity to Venofer®. Do not administer to patients with evidence of iron overload.

In efficacy studies in non-dialysis dependent-CKD patients (N=139), the most frequent adverse events (≥5%) whether or not related to Venofer® administration, were nausea (8.6%), taste disturbance

(7.9%), peripheral edema (7.2%), diarrhea (7.2%), dizziness (6.5%), hypertension (6.5%), infusion site pain or burning (5.8%), dyspnea (5.8%), and vomiting (5.0%).

In multi-dose efficacy studies in HDD-CKD patients (N=231), the most frequent adverse events (> 5%) whether or not related to Venofer® administration, were hypotension (39.4%), muscle cramps (29.4%), nausea (14.7%), headache (12.6%), graft complications (9.5%), vomiting (9.1%), dizziness (6.5%) hypertension (6.5%), chest pain (6.1%), and diarrhea (5.2%). In the study of PDD-CKD patients (N=75), the most frequent adverse events, whether or not related to Venofer®, reported by ≥5% of these patients were infections and infestations (nasopharyngitis, sinusitis, upper respiratory tract, pharyngitis) (16.0%), diarrhea (8.0%), vomiting (8.0%), hypertension (8.0%), peripheral edema (5.3%), and nausea (5.3%).


Please see Full Prescribing Information.